Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5% – Should You Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s share price traded up 5.5% on Friday . The stock traded as high as $47.00 and last traded at $47.00. 17,722 shares traded hands during trading, a decline of 93% from the average daily volume of 271,911 shares. The stock had previously closed at $44.53.

Wall Street Analyst Weigh In

Several research firms recently issued reports on COAG. Jefferies Financial Group increased their price target on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Wedbush reaffirmed an “outperform” rating and set a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a report on Monday, July 13th. Evercore started coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price objective on the stock. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Finally, The Goldman Sachs Group started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.00.

Hemab Therapeutics Trading Up 10.7%

The stock has a market capitalization of $2.30 billion and a price-to-earnings ratio of -2.06. The company has a fifty day moving average price of $30.22.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In other news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was bought at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the acquisition, the insider owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This represents a 0.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have bought 2,970,541 shares of company stock worth $55,459,603 over the last quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.